Novartis Targets Quick Launches For Zolgensma in Europe

Conditional Approval Finally Granted For SMA Gene Therapy

19 May 2020

The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.

Bootcamp_Hurdles — Novartis confident about overcoming reimbursement hurdles • Source: Shutterstock

Novartis AG has secured conditional approval in Europe for its spinal muscular atrophy therapy Zolgensma and has hit the ground running with access programs for the closely-watched gene therapy.

Just shy of two months after a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human...